An Open Label, Single Arm Phase II Study of Camrelizumab in Combination With Cisplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for Resectable HNSCC
Latest Information Update: 09 Jul 2023
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Apr 2021 New trial record